ketanserin has been researched along with dv 7028 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buczko, W; Chabielska, E; Małyszko, J; Myśliwiec, M; Pawlak, D; Pawlak, K; Takada, A | 1 |
| Adamkiewicz, M; Buczko, W; Malyszko, J; Mysliwiec, M; Pawlak, D; Takada, A | 1 |
2 other study(ies) available for ketanserin and dv 7028
| Article | Year |
|---|---|
A potent 5-hydroxytryptamine receptor (5-HT2A) antagonist, DV-7028, delays arterial thrombosis development in rats.
Topics: Animals; Aorta, Abdominal; Bleeding Time; Ketanserin; Male; Piperidines; Platelet Aggregation; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Serotonin; Serotonin Antagonists; Thrombophlebitis; Thrombosis; Triazines | 1998 |
Vascular and cardiac effects of DV-7028, a selective, 5-HT2-receptor antagonist in rats.
Topics: Animals; Baroreflex; Blood Pressure; Cardiovascular System; Coronary Circulation; Heart; Heart Rate; Hindlimb; Injections, Intravenous; Ketanserin; Male; Piperidines; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Ritanserin; Serotonin Antagonists; Triazines; Vagotomy | 1998 |